Other VMAT2 inhibitors—such as tetrabenazine, which has been associated with depression and suicidal ideation in multiple clinical trials,16 and deutetrabenazine, for which a real‐world safety analysis reported similar findings17—have been linked to these adverse effects. This evidence concerns the gene SLC18A2 and depressive symptom measurement.